Related references
Note: Only part of the references are listed.Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma
C. Ferte et al.
ANNALS OF ONCOLOGY (2010)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2010)
Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Share Paper
